Content Type: Commentary & Opinion

Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions (Reply)

March 16, 2026

The Price of Crossing the Border for Medications (Reply)

March 16, 2026

Risks to the 340B Drug Pricing Program (Reply)

March 16, 2026

Inaccurate Reporting of Insulin Reimbursement (Reply)

March 16, 2026

Health Policy Basics: The Physician Payment Sunshine Act and the Open Payments Program

March 15, 2026

High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine

March 15, 2026

The History of Health Law in the United States

March 15, 2026

Antibody Patent Evolution

March 15, 2026

Product Hopping in the Drug Industry—Lessons From Albuterol

March 15, 2026

Payments for Research Participation: Don’t Tax the Guinea Pig

March 15, 2026

Generating Evidence From Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations

March 15, 2026

Making the Case for Accelerated Withdrawal of Aducanumab

March 15, 2026